Michael Makris Shares an Update on The Safety of Andexxa
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Andexxa (andexanet alfa), the only specific anti-Xa reversal agent, has been withdrawn from the US market on December 22, 2025.
It was marketed for the reversal of Rivaroxaban and Apixaban.
The theory was great, but it was very expensive and had a higher thrombotic risk than when PCC was used for reversal.
Below is the announcement on the FDA website.
As far as I know, it is still being sold and used in Europe, but I can not see this continuing.
There is nothing on the EMA website.
Also, rather surprisingly, there is no mention of this on the AstraZeneca US or UK websites about this.
Do their medical communication teams not work in the second part of December?”
Read the full announcement here.
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal
-
Aug 26, 2026, 14:46Holly O’Byrne: A Framework for Developing and Managing Prehospital Blood Programs
-
Aug 26, 2026, 14:32Eleftherios Mylonakis: Earlier Intervention, Better Risk Stratification, Stronger BP Control
-
Aug 26, 2026, 14:32Bringing ISTH 2026 Research to the Global Scientific Community
-
Aug 26, 2026, 14:18Thomas Dayspring: Prognostic Impact of Lp(a) Changes Following Statin Therapy in Patients with CAD
-
Aug 26, 2026, 14:17Khurram Nasir: Are We Debating the Wrong Thing About Research in Medical Training?
-
Aug 26, 2026, 14:15Nathan Connell: Why Format Free Publishing Still Demands Formatting?
-
Aug 26, 2026, 14:14Reza Shojaei: China’s Reliance on Imported Albumin Raises Global Plasma Security Concerns
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM